Literature DB >> 18521287

Autocrine Transforming Growth Factor-beta Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein.

F Navid1, J J Letterio, C L Yeung, M Pegtel, L J Helman.   

Abstract

Purpose. Production of active transforming growth factor-beta (TGF-beta ) by human osteosarcoma may contribute to malignant progression through mechanisms that include induction of angiogenesis, immune suppression and autocrine growth stimulation of tumor cell growth.To study events associated with induction of cell proliferation by TGF-beta , we have evaluated the TGF-beta pathway in two murine osteosarcoma cell lines, K7 and K12.Results. Northern and immunohistochemical analyses show that each cell line expressesTGF-beta1 and TGF-beta3 mRNA and protein. Both cell lines secrete activeTGF-beta 1 and display a 30-50% reduction in growth when cultured in the presence of a TGF-beta blocking antibody. Expression of TGF-beta receptors TbetaRI, TbetaRII and TbetaRIII is demonstrated by affinity labeling with (125) -TGF-beta 1, and the intermediates, Smads 2, 3 and 4, are uniformly expressed. Smads 2 and 3 are phosphorylated in response toTGF-beta , while pRb phosphorylation in each osteosarcoma cell line is not affected by either exogenousTGF-beta or TGF-beta antibody.Conclusions. The data implicate events downstream of Smad activation, including impaired regulation of pRb, in the lack of a growth inhibitory response toTGF-beta , and indicate that this murine model of osteosarcoma is valid for investigating the roles of autocrineTGF-beta in vivo.

Entities:  

Year:  2000        PMID: 18521287      PMCID: PMC2395437          DOI: 10.1080/13577140020008057

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  59 in total

1.  Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators.

Authors:  J Yanagisawa; Y Yanagi; Y Masuhiro; M Suzawa; M Watanabe; K Kashiwagi; T Toriyabe; M Kawabata; K Miyazono; S Kato
Journal:  Science       Date:  1999-02-26       Impact factor: 47.728

Review 2.  Smads: transcriptional activators of TGF-beta responses.

Authors:  R Derynck; Y Zhang; X H Feng
Journal:  Cell       Date:  1998-12-11       Impact factor: 41.582

3.  Relation between histological intensity of transforming growth factor-beta isoforms in human osteosarcoma and the rate of lung metastasis.

Authors:  R S Yang; C T Wu; K H Lin; R L Hong; T K Liu; K S Lin
Journal:  Tohoku J Exp Med       Date:  1998-02       Impact factor: 1.848

4.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

5.  Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression.

Authors:  P Kloen; M C Gebhardt; A Perez-Atayde; A E Rosenberg; D S Springfield; L I Gold; H J Mankin
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

6.  Cyclosporine induces cancer progression by a cell-autonomous mechanism.

Authors:  M Hojo; T Morimoto; M Maluccio; T Asano; K Morimoto; M Lagman; T Shimbo; M Suthanthiran
Journal:  Nature       Date:  1999-02-11       Impact factor: 49.962

Review 7.  Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion.

Authors:  J Taipale; J Saharinen; J Keski-Oja
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

8.  Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas.

Authors:  A Franchi; L Arganini; G Baroni; A Calzolari; R Capanna; D Campanacci; P Caldora; L Masi; M L Brandi; G Zampi
Journal:  J Pathol       Date:  1998-07       Impact factor: 7.996

9.  Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells.

Authors:  A Kimchi; X F Wang; R A Weinberg; S Cheifetz; J Massagué
Journal:  Science       Date:  1988-04-08       Impact factor: 47.728

10.  Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency.

Authors:  B Tang; E P Böttinger; S B Jakowlew; K M Bagnall; J Mariano; M R Anver; J J Letterio; L M Wakefield
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  5 in total

1.  TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.

Authors:  Zaijun Lin; Dianwen Song; Haifeng Wei; Xinghai Yang; Tielong Liu; Wangjun Yan; Jianru Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-15       Impact factor: 4.553

2.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

3.  Pro-tumorigenic effects of transforming growth factor beta 1 in canine osteosarcoma.

Authors:  R F Portela; B A Fadl-Alla; H C Pondenis; M L Byrum; L D Garrett; K L Wycislo; L B Borst; T M Fan
Journal:  J Vet Intern Med       Date:  2014-03-31       Impact factor: 3.333

4.  Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.

Authors:  Vivek Subbiah; Michael J Wagner; Mary F McGuire; Nawid M Sarwari; Eswaran Devarajan; Valerae O Lewis; Shanon Westin; Shumei Kato; Robert E Brown; Pete Anderson
Journal:  Oncotarget       Date:  2015-12-01

Review 5.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

Authors:  Limin Zhu; Madonna M McManus; Dennis P M Hughes
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.